172 related articles for article (PubMed ID: 32988314)
1. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
[TBL] [Abstract][Full Text] [Related]
2. Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor.
Zuo BL; Yan B; Zheng GX; Xi WJ; Zhang X; Yang AG; Jia LT
Cancer Immunol Immunother; 2018 Mar; 67(3):393-401. PubMed ID: 29127433
[TBL] [Abstract][Full Text] [Related]
3. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.
Nellan A; Rota C; Majzner R; Lester-McCully CM; Griesinger AM; Mulcahy Levy JM; Foreman NK; Warren KE; Lee DW
J Immunother Cancer; 2018 Apr; 6(1):30. PubMed ID: 29712574
[TBL] [Abstract][Full Text] [Related]
4. [In vitro and in vivo validation of cytotoxicity of targeting human epidermal growth factor receptor-2 chimeric antigen receptor T (HER2-CAR-T) cells].
Zhang Y; Xi W; Wang P; Zhao X; Zheng R; Liang S; Meng R; Yan B; Yang A
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Apr; 40(4):289-295. PubMed ID: 38710512
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj M; Scarfò I; Cabral ML; Bailey SR; Lorrey SJ; Bouffard AA; Castano AP; Larson RC; Riley LS; Schmidts A; Choi BD; Andersen RS; Cédile O; Nyvold CG; Christensen JH; Gjerstorff MF; Ditzel HJ; Weinstock DM; Barington T; Frigault MJ; Maus MV
Clin Cancer Res; 2019 Dec; 25(23):7046-7057. PubMed ID: 31439577
[TBL] [Abstract][Full Text] [Related]
6. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity.
Helsen CW; Hammill JA; Lau VWC; Mwawasi KA; Afsahi A; Bezverbnaya K; Newhook L; Hayes DL; Aarts C; Bojovic B; Denisova GF; Kwiecien JM; Brain I; Derocher H; Milne K; Nelson BH; Bramson JL
Nat Commun; 2018 Aug; 9(1):3049. PubMed ID: 30076299
[TBL] [Abstract][Full Text] [Related]
7. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract][Full Text] [Related]
8. CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors.
Chen H; Wei F; Yin M; Zhao Q; Liu Z; Yu B; Huang Z
Cancer Immunol Immunother; 2021 Jul; 70(7):2059-2071. PubMed ID: 33439295
[TBL] [Abstract][Full Text] [Related]
9. Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol.
Yang L; Yin J; Wu J; Qiao L; Zhao EM; Cai F; Ye H
Proc Natl Acad Sci U S A; 2021 Aug; 118(34):. PubMed ID: 34404729
[TBL] [Abstract][Full Text] [Related]
10. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
Andreu-Saumell I; Rodriguez-Garcia A; Mühlgrabner V; Gimenez-Alejandre M; Marzal B; Castellsagué J; Brasó-Maristany F; Calderon H; Angelats L; Colell S; Nuding M; Soria-Castellano M; Barbao P; Prat A; Urbano-Ispizua A; Huppa JB; Guedan S
Nat Commun; 2024 Apr; 15(1):3552. PubMed ID: 38670972
[TBL] [Abstract][Full Text] [Related]
11. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.
Huo Q; Lv J; Zhang J; Huang H; Hu H; Zhao Y; Zhang X; Wang Y; Zhou Y; Qiu J; Ye Y; Huang A; Chen Y; Qin L; Qin D; Li P; Cai G
Cytotherapy; 2023 Oct; 25(10):1037-1047. PubMed ID: 37436338
[TBL] [Abstract][Full Text] [Related]
12. Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T.
Ruggeri Barbaro N; Drashansky T; Tess K; Djedaini M; Hariri R; He S; van der Touw W; Karasiewicz K
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38684370
[TBL] [Abstract][Full Text] [Related]
13. Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells.
Yoshikawa T; Ito Y; Wu Z; Kasuya H; Nakashima T; Okamoto S; Amaishi Y; Zhang H; Li Y; Matsukawa T; Inoue S; Kagoya Y
Cell Rep Med; 2024 May; 5(5):101526. PubMed ID: 38670095
[TBL] [Abstract][Full Text] [Related]
14. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
[TBL] [Abstract][Full Text] [Related]
15. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.
Hänsch L; Peipp M; Mastall M; Villars D; Myburgh R; Silginer M; Weiss T; Gramatzki D; Vasella F; Manz MG; Weller M; Roth P
Neuro Oncol; 2023 Nov; 25(11):2001-2014. PubMed ID: 37335916
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma.
Lin X; Guan T; Xu Y; Li Y; Lin Y; Chen S; Chen Y; Wei X; Li D; Cui Y; Lin Y; Sun P; Guo J; Li C; Gu J; Yang W; Zeng H; Ma C
Front Immunol; 2024; 15():1337489. PubMed ID: 38566988
[TBL] [Abstract][Full Text] [Related]
18. A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma.
Wang L; Wang X; Wu Y; Wang J; Zhou W; Wang J; Guo H; Zhang N; Zhang L; Hu X; Zhao Y; Miao J; Zhang Z; Chard Dunmall LS; Zhang D; Lemoine NR; Cheng Z; Wang Y
Cancer Lett; 2023 Aug; 568():216303. PubMed ID: 37422126
[TBL] [Abstract][Full Text] [Related]
19. Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response.
Foster JB; Choudhari N; Perazzelli J; Storm J; Hofmann TJ; Jain P; Storm PB; Pardi N; Weissman D; Waanders AJ; Grupp SA; Karikó K; Resnick AC; Barrett DM
Hum Gene Ther; 2019 Feb; 30(2):168-178. PubMed ID: 30024272
[TBL] [Abstract][Full Text] [Related]
20. Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System.
Abudureheman T; Zhou H; Yang LT; Huang XS; Jing JJ; Duan CW; Chen KM
Bioconjug Chem; 2024 May; 35(5):604-615. PubMed ID: 38661725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
